Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiepileptic Drugs: Sodium Channel Blockers01:08

Antiepileptic Drugs: Sodium Channel Blockers

1.6K
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
1.6K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

806
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
806
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

806
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
806
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

2.8K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
2.8K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

1.7K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.7K
Ligand-Gated Ion Channel Receptor: Gating Mechanism01:30

Ligand-Gated Ion Channel Receptor: Gating Mechanism

3.8K
Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
3.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Diaphragm-specific effects of L-citrulline in mdx mice highlight its potential as adjuvant of standard therapy in Duchenne muscular dystrophy.

British journal of pharmacology·2026
Same author

Best reference genes for unbiased normalized transcript expression in normal and dystrophic human cell models of myogenesis.

PloS one·2026
Same author

Rare Primary Headaches in Children: A Narrative Review.

Biomedicines·2026
Same author

Expanding the phenotypic spectrum of CACNA1A-related developmental and epileptic encephalopathy in adults.

Epileptic disorders : international epilepsy journal with videotape·2026
Same author

Selenoprotein N and SEPN1-Related Myopathies: Mechanisms, Models, and Therapeutic Perspectives.

Biomolecules·2026
Same author

State-of-the-Art Research and New Pharmacological Perspectives on Renal Involvement in Duchenne Muscular Dystrophy: A Narrative Review.

Biomedicines·2026

Related Experiment Video

Updated: Jan 13, 2026

Microtransplantation of Synaptic Membranes to Reactivate Human Synaptic Receptors for Functional Studies
10:08

Microtransplantation of Synaptic Membranes to Reactivate Human Synaptic Receptors for Functional Studies

Published on: July 20, 2022

2.5K

From Symptomatic Therapies to Disease-Modifying Approaches for Neuronal Sodium Channel Disorders.

Giorgia Dinoi1, Ileana Canfora1, Daniela D'Agnano2

  • 1Department of Pharmacy-Drug Sciences, University of Bari "Aldo Moro", Via Orabona 4, 70125 Bari, Italy.

International Journal of Molecular Sciences
|January 10, 2026
PubMed
Summary

Genetic variants in neuronal sodium channels cause neurological disorders like developmental and epileptic encephalopathies (DEEs). New precision therapies are emerging to improve seizure control and address developmental issues, moving beyond traditional symptomatic treatments.

Keywords:
Dravet syndromeETX-101elsunersenfenfluraminesodium channelszorevunersen

More Related Videos

Real-Time Fluorescent Measurement of Synaptic Functions in Models of Amyotrophic Lateral Sclerosis
08:59

Real-Time Fluorescent Measurement of Synaptic Functions in Models of Amyotrophic Lateral Sclerosis

Published on: July 16, 2021

3.1K
Chemogenetic Regulation in Reprogrammed Stem Cell-derived Precursor Cells in Treating Neurodegenerative Diseases
09:44

Chemogenetic Regulation in Reprogrammed Stem Cell-derived Precursor Cells in Treating Neurodegenerative Diseases

Published on: May 2, 2025

619

Related Experiment Videos

Last Updated: Jan 13, 2026

Microtransplantation of Synaptic Membranes to Reactivate Human Synaptic Receptors for Functional Studies
10:08

Microtransplantation of Synaptic Membranes to Reactivate Human Synaptic Receptors for Functional Studies

Published on: July 20, 2022

2.5K
Real-Time Fluorescent Measurement of Synaptic Functions in Models of Amyotrophic Lateral Sclerosis
08:59

Real-Time Fluorescent Measurement of Synaptic Functions in Models of Amyotrophic Lateral Sclerosis

Published on: July 16, 2021

3.1K
Chemogenetic Regulation in Reprogrammed Stem Cell-derived Precursor Cells in Treating Neurodegenerative Diseases
09:44

Chemogenetic Regulation in Reprogrammed Stem Cell-derived Precursor Cells in Treating Neurodegenerative Diseases

Published on: May 2, 2025

619

Area of Science:

  • Neuroscience
  • Genetics
  • Pharmacology

Background:

  • Neuronal sodium channel gene variants underlie diverse neurological disorders, notably developmental and epileptic encephalopathies (DEEs).
  • These disorders exhibit significant genetic and phenotypic variability, often accompanied by resistance to conventional antiseizure medications.
  • Current treatments, primarily symptomatic polytherapy, face limitations in efficacy and fail to address underlying developmental impairments.

Purpose of the Study:

  • To review recent advancements in treatments for neurological disorders linked to sodium channel gene variants.
  • To highlight the shift from symptomatic management to targeted, precision therapies.
  • To discuss emerging strategies and their potential in preclinical and clinical settings.

Main Methods:

  • Literature review of approved and investigational treatments for sodium channel-related neurological disorders.
  • Analysis of emerging therapeutic strategies, including antisense oligonucleotides, gene therapy, and small-molecule modulators.
  • Examination of pharmacological agents like fenfluramine, stiripentol, and cannabidiol for specific conditions such as SCN1A-related Dravet syndrome.

Main Results:

  • Sodium channel gene variants can lead to loss-, gain-, or mixed-function effects, complicating treatment selection.
  • Emerging therapies targeting SCN gene expression and function show promise in preclinical models and early clinical studies.
  • Certain non-sodium channel-targeting drugs are established treatments for specific conditions like SCN1A-related Dravet syndrome.

Conclusions:

  • There is a significant need for novel therapeutic approaches beyond current symptomatic treatments for DEEs and related disorders.
  • Precision therapies, including gene modulation and targeted small molecules, represent a promising frontier.
  • The field is transitioning towards personalized treatments that address the specific genetic underpinnings and functional consequences of sodium channel variants.